ANN ARBOR STAGE III HODGKIN LYMPHOMA
Clinical trials for ANN ARBOR STAGE III HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new ANN ARBOR STAGE III HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for ANN ARBOR STAGE III HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for seniors with hodgkin lymphoma: Chemo-Free combo shows promise
Disease control OngoingThis study tests a combination of two drugs, nivolumab and brentuximab vedotin, in people aged 60 or older (or younger people who cannot take standard chemotherapy) with untreated Hodgkin lymphoma. The goal is to see how well this drug pair works in shrinking or eliminating the c…
Matched conditions: ANN ARBOR STAGE III HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Academic and Community Cancer Research United • Aim: Disease control
Last updated Jun 15, 2026 19:06 UTC
-
Immunotherapy showdown: new hope for advanced hodgkin lymphoma patients
Disease control OngoingThis large phase 3 study compares two immunotherapy drugs (nivolumab or brentuximab vedotin) given with standard chemotherapy for people aged 12 and older with newly diagnosed, advanced-stage classical Hodgkin lymphoma. The goal is to see which combination better delays the cance…
Matched conditions: ANN ARBOR STAGE III HODGKIN LYMPHOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 11, 2026 12:09 UTC